(+91) 9810131739

Dr. Sharma's Achievements

Dr Vinod Sharma

DOCTOR'S ACHEIVEMENTS

SCIENTIFIC ADVISORY & CLINICAL RESEARCH:

More than 12 years experience in Scientific Advisory & Clinical Research as Principal Investigator with various pharmaceutical companies projects:

Clinical Research Protocol Title: GSK ITI101724

"A randomized, double blind, double-dummy, parallel group, placebo controlled study to evaluate the pharmacodynamic and pharmacokinetic response and safety and tolerability of SB424323 (250 mg, 375 mg and 500 mg, bid) administered twice daily for 16 weeks, on top of Aspirin (325 mg qd) in men and women with non valvular atrial fibrillation at a low or intermediate risk for stroke".

Clinical Research Protocol Title: KG2105255

“A dose ranging study of GSK189075 versus placebo in the treatment of Type 2 Diabetes Mellitus in treatment Naïve Subject”.

Clinical Research Protocol Title: KG2110375

“A Once daily dose ranging study of GSK189075 versus Placebo in the treatment of Type 2 Diabetes Mellitus in treatment Naïve Subject”

Torrent Research Centre

“A randomized, double blind, comparative multicentric clinical study to evaluate the safety and efficacy of Nacroandil extended release formulation in patients with chronic stable angina”.

Torrent Research Centre

“Efficacy & safety of Valsartin in patients with type 2 diabetes mellitus with or without hypertension”.

Clinical Research Protocol Title: TMC-CAN-05-03

“A Clinical trial comparing treatment with Cangrelor (in combination with usual care) to usual care in subjects who require percutaneous coronary intervention”.

Clinical Research Protocol Title

CL-3-16257-068 – “Evaluation anti-anginal efficacy and safety of oral administration of Ivabradine compared to placebo on top a background therapy with a calcium antagonists (amlodipine on nifedipine) in patients with stable angina pectoris.

Study entitled

“Multi-centre, randomized, double-blind, placebo-controlled dose escalation study to evaluate the safety and efficacy of Vanoxerine 100 mg, 200 mg and 300 mg single oral doses for conversion of patients with atrial fibrillation or atrial flutter to normal sinus rhythm (QUALTRAN LLC)

Clinical Research LPL 100601

A Clinical outcomes study of Darapladib versus Placebo in subjects with chronic coronary heart disease to compare the incidence of major adverse cardiovascular events (MACE)

RIVAROX ACS 3001

A Randomized, double-blind, Placebo-controlled, event-driven Multicenter study to evaluate the efficacy and safety of Rivaroxaban in subjects with a recent Acute coronary syndrome

TIDE Study

Thiazolidinedione Intervention with Vitamin D Evaluation (TIDE) A Multicenter Randomized double-blind Placebo-Controlled Trial of a Thiazolidinedione or Placebo and of Vitamin D or Placebo in people with Type 2 Diabetes at risk for Cardiovascular disease”

Otamixaban (XRP0673)

A randomized double-blind, triple-dummy trial to compare Otamixaban to unfractionated Heparin + Eptifibatide, in patients with unstable angina / Non ST segment elevation myocardial infarction scheduled to undergo an early invasive strategy” – TAO study – Sanofi Synthelabo

Clinical Research Protocol (No. CSPP100F2301) Title

“A multicenter, randomized, double-blind, parallel group, active-controlled study to evaluate the efficacy and safety of both aliskiren monotherapy and aliskiren / enalapril combination therapy compared to enalapril monotherapy, on morbidity and mortality in patients with chronic heart failure (NYHA Class II-IV)” – Novartis Pharma

SAVOR

Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus – “A Multicentre, Randomized, Double-Blind, Placebo-Controlled Phase IV trial to Evaluate the effect of Saxagliptin on the Incidence of Cardiovascular Death, Myocardial infarction or Ischemic Stroke in Patients with Type 2 Diabetes - AstraZeneca

Clinical Research Protocol No. NEX/AZL/CT-III-5004/05/2011

“A Double-blind, Randomized, Active Control, Prospective, Multicentric, Phase III clinical study to evaluate and compare the efficacy and safety of Azilsartanmedoxomil 40 mg and Azilsartanmedoxomil 80 mg with Telmisartan 40 mg in patients newly diagnosed with Stage 1 Hypertension”.